Treatment of Myelodysplastic Syndromes Refractory to Hypomethylating Agent
0 Views
administrator
07/04/23
Panelists discuss the limited number of treatment options that exist for patients with myelodysplastic syndromes who progress on hypomethylating agents, such as azacitidine and decitabine.
To view more from this discussion, visit http://www.onclive.com/peer-exchange/mds-cml
-
Category
Show more
Facebook Comments
No comments found